Publication: Estrogen but not testosterone preserves myofilament function from doxorubicin-induced cardiotoxicity by reducing oxidative modifications
Issued Date
2019-02-01
Resource Type
ISSN
15221539
03636135
03636135
Other identifier(s)
2-s2.0-85060960751
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Physiology - Heart and Circulatory Physiology. Vol.316, No.2 (2019), H360-H370
Suggested Citation
Chutima Rattanasopa, Jonathan A. Kirk, Tepmanas Bupha-Intr, Maria Papadaki, Pieter P. De Tombe, Jonggonnee Wattanapermpool Estrogen but not testosterone preserves myofilament function from doxorubicin-induced cardiotoxicity by reducing oxidative modifications. American Journal of Physiology - Heart and Circulatory Physiology. Vol.316, No.2 (2019), H360-H370. doi:10.1152/ajpheart.00428.2018 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50261
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Estrogen but not testosterone preserves myofilament function from doxorubicin-induced cardiotoxicity by reducing oxidative modifications
Other Contributor(s)
Abstract
© 2019 the American Physiological Society. Here, we aimed to explore sex differences and the impact of sex hormones on cardiac contractile properties in doxorubicin (DOX)-induced cardiotoxicity. Male and female Sprague-Dawley rats were subjected to sham surgery or gonadectomy and then treated or untreated with DOX (2 mg/kg) every other week for 10 wk. Estrogen preserved maximum active tension (T max ) with DOX exposure, whereas progesterone and testosterone did not. The effects of sex hormones and DOX correlated with both altered myosin heavy chain isoform expression and myofilament protein oxidation, suggesting both as possible mechanisms. However, acute treatment with oxidative stress (H 2 O 2 ) or a reducing agent (DTT) indicated that the effects on Tmax were mediated by reversible myofilament oxidative modifications and not only changes in myosin heavy chain isoforms. There were also sex differences in the DOX impact on myofilament Ca 2+ sensitivity. DOX increased Ca 2+ sensitivity in male rats only in the absence of testosterone and in female rats only in the presence of estrogen. Conversely, DOX decreased Ca 2+ sensitivity in female rats in the absence of estrogen. In most instances, this mechanism was through altered phosphorylation of troponin I at Ser 23 /Ser 24 . However, there was an additional DOXinduced, estrogen-dependent, irreversible (by DTT) mechanism that altered Ca 2+ sensitivity. Our data demonstrate sex differences in cardiac contractile responses to chronic DOX treatment. We conclude that estrogen protects against chronic DOX treatment in the heart, preserving myofilament function. NEW & NOTEWORTHY We identified sex differences in cardiotoxic effects of chronic doxorubicin (DOX) exposure on myofilament function. Estrogen, but not testosterone, decreases DOX-induced oxidative modifications on myofilaments to preserve maximum active tension. In rats, DOX exposure increased Ca 2+ sensitivity in the presence of estrogen but decreased Ca 2+ sensitivity in the absence of estrogen. In male rats, the DOX-induced shift in Ca 2+ sensitivity involved troponin I phosphorylation; in female rats, this was through an estrogen-dependent mechanism.